{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:38:44Z","timestamp":1776379124986,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the chemotherapy. To overcome these hurdles, novel therapies need to be investigated. One promising target is Polo-like kinase 1 (Plk1), a key regulator of the cell cycle. In this study, the Plk family expression is investigated in primary peripheral blood and bone marrow mononuclear cells from ten pediatric B-ALL patients. For the first time, short interfering RiboNucleic Neutrals (siRNNs) that enter cells without a transfection reagent are used to target Plk1 mRNA in primary cells from pediatric B-ALL patients. Our results show that the expression of Plk1 and Plk4 is significantly higher in pediatric B-ALL patients compared to healthy donors. Moreover, treatment of primary peripheral blood and bone marrow mononuclear cells from pediatric B-ALL patients, cultured<jats:italic>ex vivo<\/jats:italic>, with Plk1-targeting siRNNs results in cleavage of Plk1 mRNA. Importantly, the Plk1 knockdown is specific and does not affect other Plk members in contrast to many small molecule Plk1 inhibitors. Thus, Plk1 is a potential therapeutic target in pediatric B-ALL and selective targeting of Plk1 can be achieved by the use of siRNNs.<\/jats:p>","DOI":"10.1038\/s41598-020-59653-5","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:02:41Z","timestamp":1581678161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Oksana","family":"Goroshchuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Vidarsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Charlotte","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6027-1350","authenticated-orcid":false,"given":"Alexander S.","family":"Hamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Kolosenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven F.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Palm-Apergi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"59653_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","volume":"18","author":"E Steliarova-Foucher","year":"2017","unstructured":"Steliarova-Foucher, E. et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet. Oncol. 18, 719\u2013731 (2017).","journal-title":"Lancet. Oncol."},{"issue":"11","key":"59653_CR2","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","volume":"32","author":"Weili Sun","year":"2018","unstructured":"Sun, W. et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia 1\u201310, https:\/\/doi.org\/10.1038\/s41375-018-0094-0 (2018).","journal-title":"Leukemia"},{"key":"59653_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1128\/MCB.00607-10","volume":"31","author":"G de Carcer","year":"2011","unstructured":"de Carcer, G. et al. Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression. Mol. Cell. Biol. 31, 1225\u20131239 (2011).","journal-title":"Mol. Cell. Biol."},{"key":"59653_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrm3819","volume":"15","author":"S Zitouni","year":"2014","unstructured":"Zitouni, S., Nabais, C., Jana, S. C., Guerrero, A. & Bettencourt-Dias, M. Polo-like kinases: structural variations lead to multiple functions. Nat. Rev. Mol. Cell. Biol. 15, 433\u2013452 (2014).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"59653_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-018-0443-5","volume":"38","author":"O Goroshchuk","year":"2019","unstructured":"Goroshchuk, O., Kolosenko, I., Vidarsdottir, L., Azimi, A. & Palm-Apergi, C. Polo-like kinases and acute leukemia. Oncogene 38, 1\u201316 (2019).","journal-title":"Oncogene"},{"key":"59653_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1083\/jcb.200309035","volume":"164","author":"C Lindon","year":"2004","unstructured":"Lindon, C. & Pines, J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J. Cell Biol. 164, 233\u2013241 (2004).","journal-title":"J. Cell Biol."},{"key":"59653_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1083\/jcb.201205090","volume":"198","author":"D Liu","year":"2012","unstructured":"Liu, D., Davydenko, O. & Lampson, M. A. Polo-like kinase-1 regulates kinetochore-microtubule dynamics and spindle checkpoint silencing. J. Cell Biol. 198, 491\u2013499 (2012).","journal-title":"J. Cell Biol."},{"key":"59653_CR8","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1091\/mbc.e12-01-0058","volume":"23","author":"C-K Hu","year":"2012","unstructured":"Hu, C.-K., Ozlu, N., Coughlin, M., Steen, J. J. & Mitchison, T. J. Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis. Mol. Biol. Cell 23, 2702\u20132711 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"59653_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jconrel.2017.07.002","volume":"261","author":"Iryna Kolosenko","year":"2017","unstructured":"Kolosenko, I. et al. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients. J. Control. Release 261 (2017).","journal-title":"Journal of Controlled Release"},{"key":"59653_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-12-195867","volume":"114","author":"AG Renner","year":"2009","unstructured":"Renner, A. G. et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114, 659\u2013662 (2009).","journal-title":"Blood"},{"key":"59653_CR11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/leu.2009.94","volume":"23","author":"T Ikezoe","year":"2009","unstructured":"Ikezoe, T. et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 23, 1564\u201376 (2009).","journal-title":"Leukemia"},{"key":"59653_CR12","doi-asserted-by":"publisher","first-page":"1539 LP","DOI":"10.3324\/haematol.2013.084434","volume":"98","author":"SA Hartsink-Segers","year":"2013","unstructured":"Hartsink-Segers, S. A. et al. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica 98, 1539 LP\u20131546 (2013).","journal-title":"Haematologica"},{"key":"59653_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14728222.2018.1410140","volume":"22","author":"RR Maniswami","year":"2018","unstructured":"Maniswami, R. R. et al. PLK4: a link between centriole biogenesis and cancer. Expert Opinion on Therapeutic Targets 22, 59\u201373 (2018).","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"59653_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2741\/4212","volume":"19","author":"M Marina","year":"2014","unstructured":"Marina, M. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front. Biosci. 19, 352 (2014).","journal-title":"Front. Biosci."},{"key":"59653_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.7150\/jca.14307","volume":"7","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Expression of polo-like kinase 4(PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy. J. Cancer 7, 1125\u20131132 (2016).","journal-title":"J. Cancer"},{"key":"59653_CR16","unstructured":"Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2). NCT01721876 (2012). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01721876. (Accessed: 31st May 2018)."},{"key":"59653_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd.2018.132","volume":"17","author":"F Pastor","year":"2018","unstructured":"Pastor, F. et al. An RNA toolbox for cancer immunotherapy. Nat. Rev. Drug Discov. 17, 751\u2013767 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"59653_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cgt.2016.4","volume":"23","author":"E Fakhr","year":"2016","unstructured":"Fakhr, E., Zare, F. & Teimoori-Toolabi, L. Precise and efficient siRNA design: A key point in competent gene silencing. Cancer Gene Ther. 23, 73\u201382 (2016).","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"59653_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/nat.2017.0686","volume":"27","author":"Jonathan C. Hagopian","year":"2017","unstructured":"Hagopian, J. C. et al. Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers. Nucleic Acid Ther., https:\/\/doi.org\/10.1089\/nat.2017.0686 (2017).","journal-title":"Nucleic Acid Therapeutics"},{"key":"59653_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3078","volume":"32","author":"BR Meade","year":"2014","unstructured":"Meade, B. R. et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol. 32, 1256\u20131263 (2014).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"59653_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/asheducation-2006.1.128","volume":"2006","author":"Stephen E. Sallan","year":"2006","unstructured":"Sallan, S. E. Myths and lessons from the adult\/pediatric interface in acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program, 128\u2013132, https:\/\/doi.org\/10.1182\/asheducation-2006.1.128 (2006).","journal-title":"Hematology"},{"key":"59653_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2277-9531.139678","volume":"3","author":"A Musarezaie","year":"2014","unstructured":"Musarezaie, A., Khaledi, F., Esfahani, H. N. & Ghaleghasemi, T. M. Factors affecting quality of life and fatigue in patients with leukemia under chemotherapy. J. Educ. Health Promot. 3, 64 (2014).","journal-title":"J. Educ. Health Promot."},{"issue":"12","key":"59653_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrc2964","volume":"10","author":"Susanne M. A. Lens","year":"2010","unstructured":"Lens, S. M. A., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nature Reviews Cancer, https:\/\/doi.org\/10.1038\/nrc2964 (2010).","journal-title":"Nature Reviews Cancer"},{"key":"59653_CR24","unstructured":"D\u00f6hner, H. Phase III Randomized Trial of Volasertib Plus Low-Dose Cytarabine (Ldac) Versus Placebo Plus Ldac in Patients Aged >65 Years with Previously Untreated AML, Ineligible for Intensive Therapy. Available at: http:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/135257\/hartmut.dhner.phase.iii.randomized.trial.of.volasertib.plus.low-dose.html?f=m3. (Accessed: 12th April 2018)."},{"key":"59653_CR25","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","volume":"15","author":"D Rudolph","year":"2009","unstructured":"Rudolph, D. et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094\u20133102 (2009).","journal-title":"Clin. Cancer Res."},{"key":"59653_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.tips.2015.08.013","volume":"36","author":"KS Lee","year":"2015","unstructured":"Lee, K. S., Burke, T. R., Park, J. J., Bang, J. K. & Lee, E. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol. Sci. 36, 858\u2013877 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"59653_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1395","volume":"2","author":"M Raab","year":"2011","unstructured":"Raab, M. et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat. Commun. 2, 395 (2011).","journal-title":"Nat. Commun."},{"key":"59653_CR28","unstructured":"U.S. Food and Drug Administration. FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease. (2018). Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm616518.htm. (Accessed: 26th October 2018)."},{"key":"59653_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034710","author":"KK Ray","year":"2018","unstructured":"Ray, K. K. et al. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034710 (2018).","journal-title":"Circulation"},{"key":"59653_CR30","unstructured":"U.S. Food and Drug Administration. FDA approves givosiran for acute hepatic porphyria. (2019). Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-givosiran-acute-hepatic-porphyria. (Accessed: 17th December 2019)."},{"issue":"6","key":"59653_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa1807838","volume":"380","author":"Eliane Sardh","year":"2019","unstructured":"Sardh, E. et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N. Engl. J. Med., https:\/\/doi.org\/10.1056\/NEJMoa1807838 (2019).","journal-title":"New England Journal of Medicine"},{"key":"59653_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10434-001-0729-6","volume":"8","author":"JC Macmillan","year":"2001","unstructured":"Macmillan, J. C., Hudson, J. W., Bull, S., Dennis, J. W. & Swallow, C. J. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann. Surg. Oncol. 8, 729\u2013740 (2001).","journal-title":"Ann. Surg. Oncol."},{"key":"59653_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2005-03-1194","volume":"107","author":"N Syed","year":"2006","unstructured":"Syed, N. et al. Transcriptional silencing of Polo-like kinase 2 (SNK\/PLK2) is a frequent event in B-cell malignancies. Blood 107, 250\u2013256 (2006).","journal-title":"Blood"},{"key":"59653_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00277-011-1193-4","volume":"90","author":"L Benetatos","year":"2011","unstructured":"Benetatos, L. et al. Polo-like kinase 2 (SNK\/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: Genetic and epigenetic interactions. Ann. Hematol. 90, 1037\u20131045 (2011).","journal-title":"Ann. Hematol."},{"key":"59653_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.onc.1208272","volume":"24","author":"N Takai","year":"2005","unstructured":"Takai, N., Hamanaka, R., Yoshimatsu, J. & Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 24, 287\u2013291 (2005).","journal-title":"Oncogene"},{"key":"59653_CR36","unstructured":"R2: Genomics Analysis and Visualization Platform. Available at: http:\/\/r2.amc.nl. (Accessed: 5th December 2019)."},{"key":"59653_CR37","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874\u20134884 (2010).","journal-title":"Blood"},{"key":"59653_CR38","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","volume":"115","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115, 5312\u20135321 (2010).","journal-title":"Blood"},{"key":"59653_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2009-05-218560","volume":"115","author":"H Kang","year":"2010","unstructured":"Kang, H. et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115, 1394\u20131405 (2010).","journal-title":"Blood"},{"key":"59653_CR40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/rheumatology\/kew262","volume":"55","author":"J Ducreux","year":"2016","unstructured":"Ducreux, J. et al. Interferon \u03b1 kinoid induces neutralizing anti-interferon \u03b1 antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon \u03b1 kinoid phase I\/II study. Rheumatology 55, 1901\u20131905 (2016).","journal-title":"Rheumatology"},{"key":"59653_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2","author":"Hadley Wickham","year":"2009","unstructured":"Wickham, H. ggplot 2: Elagant graphics for data analysis. Media, https:\/\/doi.org\/10.1007\/978-0-387-98141-3 (2016)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59653-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T16:41:27Z","timestamp":1722444087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59653-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59653"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59653-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2688"}}